SSR240600C
Phase 2Small molecule
SanofiSSR240600C is one of 44 small molecule programs targeting Urinary incontinence. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botox
AbbViePhase 3
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
YM178
AstellasPhase 3
SPM 907
PfizerPhase 3
Onabotulinumtoxina 100 UNT
SStanford University
Phase 3
Standard Medication Therapy
QQing Yuan
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSR240600C. EMBL-EBI & Wellcome Sanger Institute.
- [4]